OOIR: Observatory of International Research

Papers

(The TQCC of Drug Resistance Updates is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Editorial Board	568
Overexpression of ABCC1 and ABCG2 confers resistance to talazoparib, a poly (ADP-Ribose) polymerase inhibitor	295
N6-methyladenosine modification of 3'tRF-AlaAGC impairs PD-1 blockade efficacy by promoting lactic acid accumulation in the tumor microenvironment of gastric carcinoma	248
Molecular subtype changes after acquiring resistance to tarlatamab in small cell lung cancer	227
Plasmid-borne tigecycline resistance gene tet(X4) in Salmonella enterica and Escherichia coli isolates from a pediatric patient with diarrhea	212
Editorial Board	212
PARP inhibition elicits NK cell-associated immune evasion via potentiating HLA-G expression in tumor	208
Unraveling the secrets: Evolution of resistance mediated by membrane proteins	202
Erratum to “A highly potent small-molecule antagonist of exportin-1 selectively eliminates CD44+ CD24- enriched breast cancer stem-like cells” [Drug Resist. Updates 66 (2023) 100903]	175
Exosomal circular RNAs: A chief culprit in cancer chemotherapy resistance	145
Unveiling the resistance to therapies in pancreatic ductal adenocarcinoma	143
Oridonin derivative DLC13 targeting proliferating cell nuclear antigen to overcome oxaliplatin resistance in colorectal cancer	143
Profiling the landscape of carbapenem resistance and hypervirulence in Klebsiella pneumoniae: A global epidemiological analysis of the plasmidome	142
Sciatic nerve stimulation enhances NK cell cytotoxicity through dopamine signaling and synergizes immunotherapy in triple-negative breast cancer	137
New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects	133
Editorial Board	131
Point mutation P174L of the penA gene endowing ceftazidime resistance to Burkholderia pseudomallei in China	130
Collateral sensitivity between tetracyclines and aminoglycosides constrains resistance evolution in carbapenem-resistant Klebsiella pneumoniae	126
Targeting DNA damage response pathways in tumor drug resistance: Mechanisms, clinical implications, and future directions	125
Replacing the tropolonic methoxyl group of colchicine with methylamino increases tubulin binding affinity with improved therapeutic index and overcomes paclitaxel cross-resistance	116
Novel insights into taxane pharmacology: An update on drug resistance mechanisms, immunomodulation and drug delivery strategies	110
A novel frameshift mutation in a case of therapy-resistant metastatic pheochromocytoma	99
A novel platinum(IV) prodrug, gramine-Pt(IV) enhances chemoimmunotherapy by activating cGAS-STING and modulating TGF-β-MHC-I axis	98
Tyrosine phosphorylation-mediated YAP1-TFAP2A interactions coordinate transcription and trastuzumab resistance in HER2+ breast cancer	91
Evolution of RND efflux pumps in the development of a successful pathogen	88

Target-based drug design strategies to overcome resistance to antiviral agents: opportunities and challenges	87
Peptide nanonet trapping suppresses bacterial motility and delays antibiotic resistance emergence	81
Inhibition of SIRT7 overcomes sorafenib acquired resistance by suppressing ERK1/2 phosphorylation via the DDX3X-mediated NLRP3 inflammasome in hepatocellular carcinoma	80
TRIM29 facilitates gemcitabine resistance via MEK/ERK pathway and is modulated by circRPS29/miR-770–5p axis in PDAC	79
The novel strategy to overcome the drug-resistant lung cancer: Dual targeting delivery of PROTAC to inhibit cancer-associated fibroblasts and lung cancer cells	77
Treatment strategies and drug resistance mechanisms in adenocarcinoma of different organs	76
Enzymatic bionanocatalysts for combating peri-implant biofilm infections by specific heat-amplified chemodynamic therapy and innate immunomodulation	73
IFNα2b modulates anti-tumor immune responses involving STAT3-associated dendritic cell dysfunction in JAK2v617f-positive myeloproliferative neoplasms	71
Drug resistance mechanisms in dopamine agonist-resistant prolactin pituitary neuroendocrine tumors and exploration for new drugs	70
The role of ABCC10/MRP7 in anti-cancer drug resistance and beyond	68
Targeting anoikis resistance as a strategy for cancer therapy	68
Editorial Board	66
Corrigendum to “RNF26 regulating tumor immunogenicity of hepatocellular carcinoma by degrading GRP78 and instigating ER stress” [Drug Resist. Updat. 86 (2026) 101375]	66
PDPN positive CAFs contribute to HER2 positive breast cancer resistance to trastuzumab by inhibiting antibody-dependent NK cell-mediated cytotoxicity	65
Heterogeneity of SOS response expression in clinical isolates of Escherichia coli influences adaptation to antimicrobial stress	65
Single-cell transcriptome analysis of patient-derived organoids captures inter- and intratumor heterogeneity and uncovers targetable pathways in high grade serous ovarian cancer	62
The role of tumor microenvironment and signaling pathways in regulating breast cancer stem cells: Implications for therapy resistance and tumor recurrence	62
Global population structure and genomic surveillance framework of carbapenem-resistant Salmonella enterica	62
Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancer	61
Emergence of silent NDM-1 carbapenemase gene in carbapenem-susceptible Klebsiella pneumoniae: Clinical implications and epidemiological insights	61
Molecular profiling of chemotherapy-resistant breast cancer reveals DNA methylation remodeling associated with the acquisition of paclitaxel resistance	59
Research progress on gene mutations and drug resistance in leukemia	58
Novel mobile colistin resistance gene mcr-4.9 in Vibrio cholerae from migratory birds	56
Inhibition of NF-κB signaling unveils novel strategies to overcome drug resistance in cancers	52
Current therapy and drug resistance in metastatic castration-resistant prostate cancer	52
Framework nucleic acid-based nanoparticles enhance temozolomide sensitivity in glioblastoma	51
Emergence of novel Klebsiella pneumoniae ST types with multidrug resistance in clinic	51
Overcoming cancer chemotherapy resistance by the induction of ferroptosis	51
Myeloid immune checkpoint blockade overcomes antibiotic resistance in bone infection by enhancing efferocytosis and suppressing MSC PANoptosis	51
Editorial Board	50
Radioiodine-refractory differentiated thyroid cancer: Molecular mechanisms and therapeutic strategies for radioiodine resistance	49
Organoid models of drug resistant gastric adenosquamous carcinoma: Recapitulating tumor features and refining precision treatment	49
Ferroptosis and the cGAS–STING pathway into precision nano-immuno-theranostics: A mechanistic paradigm for reversing drug resistance in hepatocellular carcinoma	49
Editorial Board	49
Endothelial SMAD1-MCAM axis facilitates sunitinib resistance and progression of clear cell renal cell carcinoma via LAMB1-ITGB1 signaling	48
Global distribution and genomic characteristics of carbapenemase-producing Escherichia coli among humans, 2005–2023	48
Mechanisms of therapy resistance in the tumor microenvironment: Insights from antibody array–based cytokine profiling	47
Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment	45
EMT and cancer stem cells: Drivers of therapy resistance and promising therapeutic targets	44
The role of synthetic lethality in overcoming cancer therapy resistance: Emerging paradigm and recent advances	44
Global, regional, and national disease burden of multidrug-resistant tuberculosis without extensive drug resistance, 1990–2021: Findings from the Global Burden of Disease Study 2021	44
Exosomal LOC85009 inhibits docetaxel resistance in lung adenocarcinoma through regulating ATG5-induced autophagy	43
Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade	43
Autophagy in cancer development, immune evasion, and drug resistance	42
ABCB1-dependent collateral sensitivity of multidrug-resistant colorectal cancer cells to the survivin inhibitor MX106-4C	42
Combinatorial approaches of nanotherapeutics for inflammatory pathway targeted therapy of prostate cancer	42
Combination of PD-1 blockade and neoadjuvant chemoradiotherapy benefits pMMR/MSS patients with locally advance rectal cancer: A phase 2 clinical trial	41
MicroRNA-mediated PTEN downregulation as a novel non-genetic mechanism of acquired resistance to PI3Kα inhibitors of head & neck squamous cell carcinoma	41
LncRNA DYNLRB2-AS1 promotes gemcitabine resistance of nasopharyngeal carcinoma by inhibiting the ubiquitination degradation of DHX9 protein	41
Mechanisms and determinants of bacterial susceptibility to antimicrobial Blue Light: From chromophores to transcriptomes	41

CEA-induced PI3K/AKT pathway activation through the binding of CEA to KRT1 contributes to oxaliplatin resistance in gastric cancer	40
CRISPR-Cas system as a promising player against bacterial infection and antibiotic resistance	39
RCN2 facilitates esophageal squamous cellular carcinoma metastasis and cisplatin resistance through UBR5-mediated PPP2CA ubiquitination and degradation	39
Activating ZBP1-centered PANoptosis and a collaborative innate-adaptive immune response sensitizes glioblastoma to PD-1 blockade	38
Harnessing mitochondrial metabolism and drug resistance in non-small cell lung cancer and beyond by blocking heat-shock proteins	38
Targeting SLC7A11 with sorafenib sensitizes stereotactic body radiotherapy in colorectal cancer liver metastasis	38
Acetate utilization promotes hormone therapy resistance in prostate cancer through neuroendocrine differentiation	37
Characterization difference of typical KL1, KL2 and ST11-KL64 hypervirulent and carbapenem-resistant Klebsiella pneumoniae	37
Dual specific phosphatase 4 suppresses ferroptosis and enhances sorafenib resistance in hepatocellular carcinoma	37
Un-methylation of NUDT21 represses docosahexaenoic acid biosynthesis contributing to enzalutamide resistance in prostate cancer	36
Metabolic basis of fatty acid oxidation and immunotherapy resistance with clinical perspectives	35
Cellular and molecular mechanisms of gastrointestinal cancer liver metastases and drug resistance	34
Loss of cancer-associated fibroblast-derived exosomal DACT3-AS1 promotes malignant transformation and ferroptosis-mediated oxaliplatin resistance in gastric cancer	34
Nanoparticles-mediated mitochondrial relocation of lipid-lowering drugs shape energy metabolism to conquer acquired immune resistance	33
Cuproptosis: A novel therapeutic target for overcoming cancer drug resistance	33
Folylpolyglutamate synthetase inactivation in relapsed ALL induces a druggable folate metabolic vulnerability	33
Solving the antibacterial resistance in Europe: The multipronged approach of the COST Action CA21145 EURESTOP	33
Monitoring tumour resistance to the BRAF inhibitor combination regimen in colorectal cancer patients via circulating tumour DNA	32
Endothelial cells sense temozolomide resistance to facilitate monocyte-derived macrophage infiltration in glioblastoma	31
Targeting CLK1/SRSF7 axis-dependent alternative splicing sensitizes pancreatic ductal adenocarcinoma to chemotherapy and immunotherapy	30
NDRG1 overcomes resistance to immunotherapy of pancreatic ductal adenocarcinoma through inhibiting ATG9A-dependent degradation of MHC-1	30
Emerging role of sialylation in cancer therapy resistance: Mechanisms and therapeutic implications	30
Breaking the barrier: Epigenetic strategies to combat platinum resistance in colorectal cancer	30
Advances and resistance adaptation in BTK-targeted therapy for B-cell malignancies	30
Characterization of NMCR-3, NMCR-4 and NMCR-5, three novel non-mobile colistin resistance determinants: Implications for MCR-3, MCR-7, and MCR-5 progenitors, respectively	30